Wellington Management Group LLP and affiliated entities filed Amendment No. 3 to their Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 10,742,652 shares of Cytokinetics, Incorporated common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Wellington Management Group LLP reported 10,742,652 shares of Cytokinetics common stock, representing 7.7% of the class.
- Shared voting power: Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each reported shared voting power over 9,718,250 shares.
- Shared dispositive power: The same three top-level entities each reported shared dispositive power over 10,742,652 shares, with sole dispositive power of 0.
- Wellington Management Company LLP: The operating investment adviser reported shared voting power of 9,607,635 shares and shared dispositive power of 10,210,740 shares, with an ownership percentage of 7.3%.
- Event date: The filing event triggering this amendment is dated September 30, 2026.
- Issuer address: Cytokinetics, Incorporated is headquartered at 350 Oyster Point Blvd, South San Francisco, CA, according to the filing.
Wellington's Multi-Entity Structure and Cytokinetics Ownership Chain
According to the filing, the reported shares of Cytokinetics common stock (CUSIP 23282W605) are held of record by clients of one or more investment advisers directly or indirectly owned by Wellington Management Group LLP, a Massachusetts-based holding company. The filing identifies Wellington Management Company LLP as the primary operating investment adviser, organized in Delaware, and notes that sole voting and sole dispositive power across all reporting persons stands at zero, meaning all voting and disposition authority is shared rather than individually exercised.
The filing describes a layered ownership structure in which Wellington Investment Advisors Holdings LLP controls, directly or through Wellington Management Global Holdings, Ltd., a network of Wellington investment advisers spanning the United States, Canada, Singapore, Hong Kong, the United Kingdom, Japan, and Australia. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP, which in turn is owned by Wellington Management Group LLP. Each entity in this chain reported the same aggregate beneficial ownership figure of 10,742,652 shares at 7.7% of the class, as stated on the respective cover pages of the amendment.
The filing further states, in its Item 10 certification, that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Cytokinetics, Incorporated is a South San Francisco-based biopharmaceutical company focused on muscle biology, and this Schedule 13G amendment reflects a passive institutional ownership disclosure rather than an activist or control-seeking position, per the certification language in the filing.
What Was Disclosed
Wellington Management Group LLP and three affiliated entities filed Amendment No. 3 to Schedule 13G, reporting aggregate beneficial ownership of 10,742,652 Cytokinetics common shares, equal to 7.7% of the class, as of the September 30, 2026 event date.




Please wait processing your request...